Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

  • STATUS
    Recruiting
  • End date
    Dec 9, 2021
  • participants needed
    66
  • sponsor
    Seoul National University Hospital
Updated on 23 January 2021

Summary

NCCN guidelines for B cell lymphoma suggest that patients with relapsed/refractory aggressive NHL who are candidate for high-dose therapy should receive combination of cytotoxic chemotherapies as 2nd line treatment. However, proportion of patients who are adequately salvaged by second line chemotherapy and high-dose chemotherapy with stem cell rescue is unsatisfactory. Moreover, many fragile patients are unfit for salvage cytotoxic chemotherapy and/or high-dose chemotherapy. Hence, most of patients with relapsed/refractory aggressive B-cell NHL is ultimately candidate for less-cytotoxic drugs with targeted approach. This trial is phase II trial of acalabrutinib in combination with rituximab and lenalidomide for these patients.

Details
Condition Non-hodgkin Lymphoma,B Cell
Treatment acalabrutinib
Clinical Study IdentifierNCT04094142
SponsorSeoul National University Hospital
Last Modified on23 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Do you have Non-hodgkin Lymphoma,B Cell??
Men and women 18 years of age
Diagnosed with aggressive B cell non-Hodgkin lymphoma
Diffuse large B cell lymphoma (Both GCB and non-GCB)
GCB type should not be more than 40% (N=26) of whole study population (Would
limit number of GCB patients by maximum of 26)
Primary mediastinal B cell lymphoma
Transformed follicular lymphoma
Small lymphocytic lymphoma with Richter transformation 3. Failed previous treatments and last dose administered must be more than 2-week ahead from enrollment
Should have received anti-CD20 based chemotherapy previously
Failed at least two lines of therapy if patient is candidate for autologous stem cell transplantation
Failed frontline therapy if patient is ineligible for autologous stem cell transplantation 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 5. Woman of childbearing potential (WOCBP) who are sexually active must have 2 negative urine hCG test prior to first dose, then every week for the first month of study period, then every 4 weeks afterwards during treatment period if menses are regular or every 2 weeks if menses are irregular. Urine hCG test must be done 4 weeks after the last dose of acalabrutinib, lenalidomide and rituximab. WOCBP must use 2 methods including at least 1 highly effective method of contraception for 4 weeks prior to first dose, during treatment period and for 4 weeks after the last dose of acalabrutinib, lenalidomide and for 12 months after the last dose of rituximab. Men who are sexually active must use condoms during treatment period and 4 weeks after the last dose of any study drug. 6. Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty. 7. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information

Exclusion Criteria

Diagnosed with mantle cell lymphoma
Previously treated with more than four lines of chemotherapy (Consolidative autologous stem cell transplantation is deemed as the same line therapy)
Previously treated with allogeneic hematopoietic stem cell transplantation within 6 months
GVHD requiring treatment
Patient who cannot take drug per oral
Known resistance to both BTK inhibitor and lenalidomide (Progression free survival to both BTK inhibitor and lenalidomide < 6 months)
Known resistant mutation to BTK inhibitor (BTKC481S and PLGCR665W)
Prior malignancy (or any other malignancy that requires active treatment), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for 5 years or which will not limit survival to < 5 years
Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification. Subjects with controlled, asymptomatic atrial fibrillation during screening can enroll on study
Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass
Known history of infection with HIV or any uncontrolled active systemic infection (eg, bacterial, viral or fungal)
Known history of drug-specific hypersensitivity or anaphylaxis to study drug (including active product or excipient components)
Active bleeding, history of bleeding diathesis (eg, hemophilia or von Willebrand disease)
Uncontrolled AIHA (autoimmune hemolytic anemia) or ITP (idiopathic thrombocytopenic purpura)
Requires treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor/inducer
Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists (eg, phenprocoumon) within 7 days of first dose of study drug
Prothrombin time/INR or aPTT (in the absence of Lupus anticoagulant) > 2x ULN
Requires treatment with proton pump inhibitors (eg, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Subjects receiving proton pump inhibitors who switch to H2-receptor antagonists or antacids are eligible for enrollment to this study
History of significant cerebrovascular disease or event, including stroke or intracranial hemorrhage, within 6 months before the first dose of study drug
Major surgical procedure within 28 days of first dose of study drug. Note: If a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug
Hepatitis B or C serologic status: subjects who are hepatitis B core antibody (anti-HBc) positive and who are surface antigen negative will need to have a negative polymerase chain reaction (PCR). Those who are hepatitis B surface antigen (HbsAg) positive or hepatitis B PCR positive will be excluded. Those who are positive only for anti-HBc and negative for HbsAg and hepatitis B PCR need to receive adequate antiviral prophylaxis for hepatitis B during the study period
Subjects who are hepatitis C antibody positive will need to have a negative
PCR result. Those who are hepatitis C PCR positive will be excluded
\. Active tuberculosis (history of exposure or history of positive
tuberculin test; plus presence of clinical symptoms, physical or radiographic
findings). Subjects with latent tuberculosis infection who are deemed to
require treatment by the investigator are not eligible
\. Uncontrolled active infection as determined by the investigator
\. WBC < 3,000 /L, ANC < 1,000 /L, Platelets < 75,000 /L, or Hemoglobin <
0 g/dL. Correction with transfusion within 2 weeks is not allowed
\. Total bilirubin > 2 x ULN, or AST, ALT > 3 x ULN
\. Cr > 1.5 x ULN or CLcr < 30 mL/min/1.73m2
\. Breastfeeding or pregnant
\. Concurrent participation in another therapeutic clinical trial
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note